Rustam Turakulov

Rustam Turakulov

Auto-generated profile, based on publicly available information

Rustam Turakulov

Tashkent State Medical University

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 June 2025 in Developmental Neurobiology
Verified
Journal Article
Closed access
AAAbdulla A. Al‐Dulaimi
Abdulla A. Al‐Dulaimi
TRTurakulov Rustam
Turakulov Rustam
MJMahmood Jawad
Mahmood Jawad
NKNina N. Kanshina
Nina N. Kanshina
LBLalji Baldaniya
Lalji Baldaniya
ZAZainab Ahmed Abass
Zainab Ahmed Abass

23 January 2026 in Primary Health Care (Russian Federation)
Verified
Journal Article
Open access
PDF file
ODOxana M. Drapkina
Oxana M. Drapkina
RSR. N. Shepel
R. N. Shepel
OKO. Yu. Kuznetsova
O. Yu. Kuznetsova
AKA. V. Korotkova
A. V. Korotkova
NBN. N. Brimkulov
N. N. Brimkulov
АХА. Ж. Хасенова
А. Ж. Хасенова
Aim . To assess the current status and identify prospects for harmonizing the training of ge­neral practitioners (GP) (family physicians (FP)) in individual members of the Common­wealth of Independent States (CIS) to improve the quality of primary health care (PHC). Material and methods . The study data was collected and analyzed in 2025 by researchers from leading medical universities in the CIS member states as part of the international research project GP-FP using specially developed questionnaires. Research methods inclu­ded statistical, analytical, and contextual comparison. Results . An analysis of regulatory data regarding GP-FP training revealed similar models of ma­naging PHC as the foundation of the entire healthcare system, the systematic GP-FP im­ple­mentation, and the use of the territorial-­district principle, as well as some differences. A comparison of country data on educational and professional standards and residency training programs revealed convergence across most parameters. The country data is sys­tema­tized and presented in tabular format. Conclusion . The significant similarities and some differences in the training and professional activities of GP-FP highlight the potential for harmonizing programs, requirements, and the regulatory framework for training these specialists across the CIS and, accordingly, outlined areas for further research.

10 September 2022 in Nephrology (Saint-Petersburg)
Verified
Journal Article
Closed access
PDF file
AGA. G. Gadaev
A. G. Gadaev
RTR. I. Turakulov
R. I. Turakulov
NPN. V. Pirmatova
N. V. Pirmatova
FHF. I. Hudjakulova
F. I. Hudjakulova
   THE AIM: to evaluate the functional reserve of the kidneys (FRK), and the effectiveness of empagliflozin (EMPA), a selective reversible inhibitor of sodium-glucose cotransporter type 2 (SGLT 2), in patients with chronic heart failure who have had COVID-19 infection.   PATIENTS AND METHODS: To assess the state of renal function in patients with coronary heart disease (CHF), the most accessible and convenient method for determining FRK using 0.45 % saline was chosen. The study involved 110 patients with CHF developed as a result of coronary artery disease and hypertension. The first group consisted of 40 patientswith CHF who have had COVID-19 infection (16 (40 %) men and 24 (60 %) women, mean age 63.2 ± 1.2 years). They received EMPA in addition to standard therapy. The second group consisted of 40 patients with CHF who have also had COVID-19 (24 (60 %) men and 16 (40 %) women, mean age 64.1 ± 1.2 years). They received only standard therapy (ACE inhibitors or ARB,beta-blockers, AMCR). The control group consisted of 30 CHF patients who haven’t had COVID-19 infection (16 (53.33 %) men and 14 (46.67 %) women, mean age 61.8 ± 1.2 years). They received only standard therapy.   RESULTS. In patients of the first group (standard treatment+ EMPA) the FRK was 2.9 ± 0.2 % before and 8.1 ± 0.2 % after the treatment, which indicates a significant increase (p<0.001). The creatinine level before the treatment and exercise was 147.7±2.7 μmol/l, and after the exercise, it decreased to 144.7±2.5 μmol/l. After the standard therapy, a decrease in its index by 102.5±1.4 μmol/l and 99.7 ± 1.3 μmol/l, respectively, was established. The glomerular filtration rate before treatment and exercise was 56.8 ± 1.5 ml/min, and after exercise, it increased to 54.3 ± 1.6 ml/min. After the treatment, these values were 60.3 ± 2.01 ml/min and 62.7±2.08 ml/min, respectively. In patients of the second group (standard treatment), FRK was 4.4 ± 0.1 % before and 3.0 ± 0.2 % after treatment.   CONCLUSION: Thus, in patients of the first group, who received EMPA along with standard CHF treatment, an increase in FRK by 2.8 times was found (p < 0.01). In the group of patients with CHF who did not receive an inhibitor of sodium-glucose transporter type 2 EMPA in combination with standard therapy, a decrease in FRK by 1.3 times was found (p > 0.05). While in the control group, FRK increased by 1.1 times (p > 0.05). Thus, the results show that in the first group, the FRK index was 2.9 %, which indicates the absence of a reserve, while after complex therapy in combination with EMPA, this increased to 8.1 %, which indicates the presence of a reserve. However, in the second group, the decrease in these indicators from 4.4 % to 3.3 %, respectively, suggests the absence of FRK. In the control group, this figure increased from 6.7 % before treatment to 7.1 % after.This indicates a decrease in FRK in this group of patients. Thus, the decrease in the FRK in patients of the first group compared with the control indicates an adverse effect of COVID-19 on the kidneys. It is confirmed in numerous studies, which makes us think about its long-term effect not only in the acute period of infection but also after the clinical convalescence.

27 February 2026 in Medical science of Uzbekistan
Verified
Journal Article
Open access
PDF file
AGAbdigaffor G. Gadayev
Abdigaffor G. Gadayev
RTRustam I. Turakulov
Rustam I. Turakulov
BNBakhtiyor A. Nurullayev
Bakhtiyor A. Nurullayev
Chronic obstructive pulmonary disease (COPD) and congestive heart failure (CHF) are among the leading causes of morbidity and mortality in the world. The high comorbidity burden presents important clinical challenges in exacerbating the issues of diagnosis and treatment due to overlapping symptom profiles, shared risk factors, and interconnected pathophysiological processes. This narrative review summarizes recent evidence on the epidemiology, pathophysiology, diagnostic challenges and therapeutic strategies for these patients. Peer-reviewed studies were identified by conducting a systematic search of PubMed, MEDLINE, and EMBASE from 2016 to 2024. Existing data suggests that COPD occurs in 20–30\% of patients with CHF, and a comparable proportion of moderate-to-severe COPD has left ventricular dysfunction. Coginitive impairment is an independent predictor of adverse clinical outcomes, including higher rates of hospitalization and mortality. Systemic inflammation, oxidative stress, skeletal muscle dysfunction and neurohormonal activation are shared pathways linking these different diseases. Differential diagnosis is limited because of clinical symptom overlap; however, each mentioned biomarker has complementary diagnostic utility in general: natriuretic peptides will identify pulmonary hypertension due to left heart failure, echocardiography can assess underlying structural heart disease and pulmonary function testing helps characterize the underlying pathology. Management should be a personalized and multi-faceted approach focusing on drug safety related to beta-blockers and bronchodilators along with non-pharmacologic strategies such as pulmonary rehabilitation and cardiac rehabilitation. This review underscores the need for joint clinical assessment and supports more prospective studies of this high-risk group.

30 March 2026 in Engineering Perspectives in Filtration and Separation
Verified
Journal Article
Closed access
RTRustam Turakulov
Rustam Turakulov
Pharmaceutical contaminations of wastewater have become a major environmental problem since traditional water treatments may be inefficient in the complete removal of biologically active contaminants. This research is aimed at providing an environmentally sustainable method of zinc oxide (ZnO) nanoparticles preparation using leaf extract of Moringa oleifera and testing their ability to photocatalyze diclofenac decomposition in wastewater. The proposed green synthesis method involves aqueous plant extract as the medium for the reduction and stabilization of nanoparticles. Characterization of the synthesized ZnO nanoparticles in terms of their structural properties, particle morphology, and functional groups present on the surface will be performed through relevant characterization methods. Performance of photocatalysis will be tested in a light exposure test with respect to parameters such as dosage of the catalyst, pH of the solution, time of irradiation, and reusability of the catalyst. Concentration of diclofenac before and after photocatalysis will be analyzed using an analytical method. A dark adsorption test and irradiation-only control test will be conducted in order to differentiate photocatalysis from adsorption and photolysisIt is expected to generate a result in the form of the determination of appropriate operational parameters for the removal of diclofenac and evaluation of the possibility of recycling of the catalyst. In general, the use of plant-derived ZnO nanoparticles could be considered as a prospective approach towards pharmaceutical wastewater treatment in an eco-friendly manner.

12 August 2026 in MedicineProblems.uz-Topical Issues of Medical Sciences
Verified
Journal Article
Open access
PDF file
MNMa’RUfjon Norqulov
Ma’RUfjon Norqulov
RTRustam Turaqulov
Rustam Turaqulov
Bilan komorbidlikda kechgan bemorlarda aortokoronar shuntlash (AKSh) amaliyotining jigar funksional holati, adipokin-sitokin muvozanati va to‘qima elastikligiga ta’sirini baholash hamda gepatoprotektor korreksiyaning samaradorligini aniqlash. Materiallar va usullar. Ko‘p tomirli koronar zararlanish aniqlanib AKSh o‘tkazilgan 120 nafar bemor tekshirildi: asosiy guruh – stenokardiya MAJYOK bilan kechgan 100 bemor, nazorat guruhi – jigar patologiyasi aniqlanmagan 20 bemor. Ko‘rsatkichlar amaliyotdan oldin, undan 2 kun va 6 oy keyin baholandi. Asosiy guruh 6 oylik davo rejimiga ko‘ra ikkiga ajratildi (standart davo, n=50; standart davo + ademetionin, n=50). Natijalar. Amaliyotdan oldin asosiy guruhda MELD (8,9±0,23 va 7,6±0,2), FLI (77,3±0,74 va 22,7±0,18), leptin (27,7±0,7 va 17,5±0,9 ng/ml), IL-6 (9,2±0,4 va 5,4±0,4 pg/ml), α-O‘NO (12,3±0,45 va 7,4±0,37 pg/ml) va Yung moduli medianasi (8,62±0,17 va 5,53±0,2 kPa) ishonchli yuqori, adiponektin (5,4±0,14 va 6,9±0,31 mkg/ml) hamda grelin (564,5±14,4 va 661,7±28,9 pg/ml) ishonchli past bo‘ldi (p<0,01–0,001). Amaliyotdan keyingi 2-kunda sitolitik, xolestatik va yallig‘lanish ko‘rsatkichlari oshdi; 6-oyga kelib an’anaviy laborator ko‘rsatkichlar me’yorlashdi, ammo adiponektin (4,7±0,18 mkg/ml), leptin (29,2±0,6 ng/ml), IL-6 (11,1±0,3 pg/ml), α-O‘NO (15,1±0,44 pg/ml) va Yung moduli medianasi (8,86±0,09 kPa) boshlang‘ich darajaga qaytmadi. Ademetionin qo‘shilgan kompleks davo ushbu ko‘rsatkichlarning barchasini ishonchli yaxshiladi (p<0,05–0,001). Xulosa. MAJYOK fonida o‘tkazilgan AKSh amaliyoti an’anaviy laborator ko‘rsatkichlar me’yorlashganidan keyin ham saqlanadigan subklinik gepatometabolik va yallig‘lanish buzilishlari bilan kechadi; ularni aniqlashda adipokin-sitokin paneli va elastometriya axborotli, korreksiyasida esa gepatoprotektor terapiya samarali.